Repare Therapeutics : Initial TRESR data provide clinical proof of concept and validate Repare Therapeutics' SNIPRx platform for molecular selection of tumors for therapy with RP-3500 - Form 8-K
Initial TRESR data provide clinical proof of concept and validate Repare Therapeutics SNIPRx platform for molecular selection of tumors for therapy with RP-3500 ... | October 8, 2021
Source: marketscreener.com